IntelGenx Technologies Corp. Form 8-K December 14, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

December 14, 2016

Date of Report (Date of Earliest Event Reported)

INTELGENX TECHNOLOGIES CORP.

(Exact Name of Registrant as Specified in its Charter)

Delaware (State or other jurisdiction of

incorporation)

000-31187 (Commission File Number) 870638336 (IRS Employer Identification No.)

H4S 1Y2

<u>6420 Abrams, Ville St- Laurent, Quebec, Canada</u>

(Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (514) 331-7440

Check the appropriate box below if the Form 8K fining is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[] Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[] Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 8.01 Other Events - News Release

IntelGenx and Red Hill Biopharma Announce Definitive Agreement for Commercialization of RIZAPORT[®] for Migraines with Pharmatronic Co. in South Korea

ExhibitDescription99.1Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTELGENX TECHNOLOGIES CORP.

Dated: December 14, 2016

By: /s/ Horst G. Zerbe Horst G. Zerbe President and Chief Executive Officer